NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2015
CVR: 24257924
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2015. In 2015, the company reported a net result of DKK 1,879,000 compared with DKK 3,150,000 the year before. Equity in the 2015 report amounted to DKK 14,422,000. The solvency ratio was 99.9%.
- Profit/Loss
- DKK 1,879,000
- Equity
- DKK 14,422,000
- Total Assets
- DKK 14,442,000
Official annual report
How creditworthy is NOVO NORDISK PHARMACEUTICALS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of April 30, 2015, Lars Fruergaard Jørgensen has joined the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
As of April 30, 2015, Kåre Schultz has left the board of directors of NOVO NORDISK PHARMACEUTICALS A/S.
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2014. The net result was DKK 3,150,000.
About NOVO NORDISK PHARMACEUTICALS A/S
NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.
